SCHEMBL20090601

SCHEMBL20090601

C#Cc1cc(N/C(=N\O)c2nonc2NCCS(C)(=N)=N)ccc1F

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 20/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23066855 1.00 IDO1 (0.49) IDO1
SCHEMBL23066825 0.91 IDO1 (0.47) IDO1
SCHEMBL23066822 0.91 IDO1 (0.47) IDO1
SCHEMBL20198991 0.88 IDO1 (0.51) IDO1
SCHEMBL20199336 0.87 IDO1 (0.47) IDO1
SCHEMBL23066860 0.87 IDO1 (0.46) IDO1
SCHEMBL20199011 0.87 IDO1 (0.46) IDO1
SCHEMBL29042716 0.86 IDO1 (0.57) IDO1
SCHEMBL30449546 0.86 IDO1 (0.57) IDO1
SCHEMBL30449667 0.86 IDO1 (0.57) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168078-B2 Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2021-11-09 US disclosed
US-11168078-B2 Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2021-11-09 US disclosed
US-20210070742-A1 SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOCHON BIOSCIENCES, LTD. (CN) 2021-03-11 US disclosed
US-20210070742-A1 SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOCHON BIOSCIENCES, LTD. (CN) 2021-03-11 US disclosed
WO-2018095432-A1 SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASE SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2018-05-31 WO disclosed
WO-2018072697-A1 OXADIAZOLE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, COMPOSITE, AND APPLICATION THEREOF 上海医药集团股份有限公司 2018-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070742-A1 SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TST IDO1 1/4885
US-11168078-B2 Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase IDO1, IDO2, TST IDO1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.